GCG and diabetes mellitus: Therapies that target incretin pathways, particularly those aimed at the glucagon-like peptide-1 (GLP-1) axis, have significantly advanced the management of diabetes by supporting better glycemic outcomes, facilitating weight reduction, and delivering cardiovascular risk reduction [2].